NCT05157841View on ClinicalTrials.gov

Phase 3, Sciatic Nerve Block With EXPAREL for Subjects Undergoing Bunionectomy

PHASE3CompletedINTERVENTIONAL
Enrollment

185

Participants

Timeline

Start Date

February 15, 2022

Primary Completion Date

August 17, 2022

Study Completion Date

August 17, 2022

Conditions
BunionectomyHallux Valgus
Interventions
DRUG

Bupivacaine liposome injectable suspension 266 mg

Sciatic nerve block in the popliteal fossa with EXPAREL 266 mg

DRUG

Bupivacaine HCl

Sciatic nerve block in the popliteal fossa with Bupivacaine HCl

DRUG

Bupivacaine liposome injectable suspension 133 mg

Sciatic nerve block in the popliteal fossa with EXPAREL 133 mg

Trial Locations (7)

45417

Midwest Clinical Research Center, Dayton

72118

Arkansas Surgical Hospital, North Little Rock

75006

HD Research-Legent Orthopedic Hospital, Carrollton

77008

Houston Heights Hospital, Houston

77401

HD Research- First Surgical Hospital, Bellaire

78240

Endeavor Clinical Trials, San Antonio

91105

Lotus Clinical Research, Pasadena

Sponsors
All Listed Sponsors
lead

Pacira Pharmaceuticals, Inc

INDUSTRY

NCT05157841 - Phase 3, Sciatic Nerve Block With EXPAREL for Subjects Undergoing Bunionectomy | Biotech Hunter | Biotech Hunter